<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240379</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.146</org_study_id>
    <secondary_id>2019-A01278-49</secondary_id>
    <nct_id>NCT04240379</nct_id>
  </id_info>
  <brief_title>Metacognition Assessment in Patient With Multiple Sclerosis</brief_title>
  <acronym>METACOGSEP</acronym>
  <official_title>Metacognition Assessment in Patient With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Grenoble Alps</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assessed the level of consciousness of MS patients suffering of cognitive and&#xD;
      motor disorders. Understanding the awareness of the disease is crucial to allow better&#xD;
      management of these patients. It has been shown, for other neurological pathologies, that a&#xD;
      lack of awareness of deficits leads to inefficient rehabilitation and a disorder of&#xD;
      understanding the impact of deficits in daily activities. Metacognition could be altered with&#xD;
      age, so we will include participants between 18 and 60 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject who have to do neurological assessement by the Multiple sclerosis Functional&#xD;
      Composite (MSFC) will be enrolled.&#xD;
&#xD;
      The patient will estimate the time to undergo the test. This time will be compared to the&#xD;
      time really make by the patient to realise test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">April 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metacognitive precision</measure>
    <time_frame>Day 1</time_frame>
    <description>Metacognitive precision based on Multiple Sclerosis Functional Composite (MSFC) score</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be proposed to subject :&#xD;
&#xD;
          -  Male or female with diagnosis of MS,&#xD;
&#xD;
          -  admitted in neurological unit for passing the MSFC (Multiple Sclerosis Functionnal&#xD;
             Composite) test&#xD;
&#xD;
          -  who respect selection criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple sclerosis&#xD;
&#xD;
          -  Voluntary for participate to study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological disease other than Multiple Sclerosis&#xD;
&#xD;
          -  psychiatric disease, other than depressiveness&#xD;
&#xD;
          -  illicit substance abuse&#xD;
&#xD;
          -  Persons referred to in Articles L1121-5 to 8 of the French Public Health Code&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Audrey MAZANCIEUX, PhD</last_name>
    <phone>33 6 41 99 61 52</phone>
    <email>audrey.mazancieux@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier CASEZ, MD</last_name>
    <phone>33 4 76 76 58 71</phone>
    <email>OCasez@chu-grenbole.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey MAZANCIEUX</last_name>
    </contact>
    <investigator>
      <last_name>Olivier CASSEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Calabrese P. Neuropsychology of multiple sclerosis--an overview. J Neurol. 2006 Feb;253 Suppl 1:I10-5. Review.</citation>
    <PMID>16477479</PMID>
  </reference>
  <reference>
    <citation>Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008 Dec;7(12):1139-51. doi: 10.1016/S1474-4422(08)70259-X. Review.</citation>
    <PMID>19007738</PMID>
  </reference>
  <results_reference>
    <citation>Beatty WW, Monson N. Metamemory in multiple sclerosis. J Clin Exp Neuropsychol. 1991 Mar;13(2):309-27.</citation>
    <PMID>1688342</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Multiple Sclerosis Functional Composite (MSFC)</keyword>
  <keyword>Metacognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

